Next Article in Journal
A Mini-Review: Clinical Development and Potential of Aptamers for Thrombotic Events Treatment and Monitoring
Next Article in Special Issue
Role of Muscarinic Acetylcholine Signaling in Gastrointestinal Cancers
Previous Article in Journal
A Brief Overview of the Antitumoral Actions of Leelamine
Previous Article in Special Issue
The Function of Lgr5+ Cells in the Gastric Antrum Does Not Require Fzd7 or Myc In Vivo
Article Menu

Export Article

Open AccessReview

Management of Bleeding from Unresectable Gastric Cancer

Department of Gastroenterology, Kyoto Okamoto Memorial Hospital, 100 Nishinokuchi, Sayama, Kumiyama-cho, Kuze-gun, Kyoto 613-0034, Japan
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(3), 54;
Received: 29 May 2019 / Revised: 15 July 2019 / Accepted: 19 July 2019 / Published: 24 July 2019
(This article belongs to the Special Issue Gastric Cancer Research: From Basic Science to the Clinic)
PDF [1892 KB, uploaded 24 July 2019]
  |     |  


Bleeding from unresectable gastric cancer (URGC) is not a rare complication. Two major ways in which the management of this issue differs from the management of benign lesions are the high rate of rebleeding after successful hemostasis and that not only endoscopic therapy (ET) and transcatheter arterial embolization (TAE) but palliative radiotherapy (PRT) can be applied in the clinical setting. However, there are no specific guidelines concerning the management of URGC with bleeding. We herein discuss strategies for managing bleeding from URGC. A high rate of initial hemostasis for active bleeding is expected when using various ET modalities properly. If ET fails in patients with hemostatic instability, emergent TAE is considered in order to avoid a life-threating condition due to massive bleeding. Early PRT, especially, regimens with a high biologically effective dose (BED) of ≥39 Gy should be considered not only for patients with hemostatic failure but also for those with successful hemostasis and inactive hemorrhage, as longer duration of response with few complications can be expected. Further prospective, comparative studies considering not only the hemostatic efficacy of these modalities but the patients’ quality of life are needed in order to establish treatment strategies for bleeding from URGC. View Full-Text
Keywords: gastric cancer; bleeding; endoscopy; transcatheter arterial embolization; palliative radiotherapy gastric cancer; bleeding; endoscopy; transcatheter arterial embolization; palliative radiotherapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kawabata, H.; Hitomi, M.; Motoi, S. Management of Bleeding from Unresectable Gastric Cancer. Biomedicines 2019, 7, 54.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top